RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - RxSight, Inc. reported a quarterly loss of $0.04 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.19, marking an earnings surprise of +78.95% [1] - The company generated revenues of $30.34 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 19.02%, although this represents a decline from $35.31 million in the same quarter last year [2] - RxSight shares have declined approximately 73.8% year-to-date, contrasting with a 15.1% gain in the S&P 500 [3] Earnings Outlook - The earnings outlook for RxSight is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.15 on revenues of $28.68 million, and -$0.56 on revenues of $125.7 million for the current fiscal year [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which RxSight belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]